UC San Diego Recruiting Participants for Advanced Prostate Cancer Clinical Trials


UC San Diego Recruiting Participants for Advanced Prostate Cancer Clinical Trials

The University of California, San Diego (UCSD) is currently enrolling men with advanced prostate cancer (metastatic castration-resistant prostate cancer, or mCRPC) in several promising clinical trials. These studies aim to test new treatments that may improve outcomes and quality of life for patients. Here’s what you need to know:

1. Abivertinib and Abiraterone Combination Trial

  • What’s being tested? This study is looking at whether adding abivertinib, a targeted therapy, to the standard prostate cancer drug abiraterone can help slow cancer growth.

  • Who can participate? Men with mCRPC, whether they are new to abiraterone treatment or have already tried it.

  • Timeline: The trial is expected to run until January 2028.

  • Why it matters: Abivertinib works differently from standard prostate cancer treatments and may help patients whose cancer has become resistant to other therapies.

2. Cabozantinib and Nivolumab Combination Therapy

  • What’s being tested? This trial is studying a combination of two drugs—cabozantinib, which may slow tumor growth, and nivolumab, an immunotherapy that helps the body fight cancer.

  • Who can participate? Men with advanced prostate cancer that has stopped responding to hormone therapy.

  • Timeline: The study started in 2023 and is expected to continue until 2027, with about 50 participants.

  • Why it matters: Combining these two treatments may offer a new way to control prostate cancer for men who have few other options.

3. Vudalimab (XmAb20717) for Prostate Cancer

  • What’s being tested? A new drug called vudalimab, which boosts the immune system’s ability to fight cancer.

  • Who can participate? Men with advanced prostate cancer that has spread and is no longer responding to standard treatments.

  • Timeline: The trial is expected to finish in September 2025 and aims to enroll 85 patients.

  • Why it matters: Immunotherapy has shown promise in many types of cancer, and this study hopes to see if it can be effective for prostate cancer patients.

How to Get Involved

If you or a loved one is living with advanced prostate cancer and are interested in learning more about these trials, talk to your doctor about whether participating might be a good option. You can also visit UCSD’s clinical trials website or contact their Clinical Trials Office for details.

Clinical trials give patients access to cutting-edge treatments while also helping researchers find better ways to fight prostate cancer. If you’re considering a trial, your healthcare team can help you weigh the benefits and risks to make the best decision for your health.

Stay informed and keep an eye on new research—your involvement could make a difference in the future of prostate cancer treatment.

Comments

Post a Comment

Popular posts from this blog

A 10-Second Steam Blast: The New Weapon Against Prostate Cancer?

Image
Vanquish® Water Vapor Ablation System, Francis Medical Steams Out Prostate Cancer The Vanquish® Water Vapor Ablation System, developed by Francis Medical, Inc. , represents an innovative approach to treating prostate cancer using water vapor (steam) to ablate cancerous tissue. This minimally invasive technique aims to target and destroy prostate cancer cells while minimizing damage to surrounding healthy tissue, potentially reducing common side effects associated with traditional treatments like surgery and radiation, Mechanism of Action:  The Vanquish system utilizes the thermal energy stored in sterile water vapor to ablate cancerous prostate tissue. During the procedure, a catheter is inserted through the urethra into the prostate, delivering water vapor directly to the targeted tissue. As the vapor condenses back into liquid, it releases stored thermal energy, effectively destroying the cancerous cells. This method is designed to respect the prostate's natural boundaries, ...
Read more

Researchers develop low-cost device that detects cancer in an hour | ScienceDaily

Image
Summary Sanjay S. Timilsina , currently Lead Scientist, StataDx, a spinoff from Wyss Institute, former Postdoctoral Fellow at Harvard Medical School and the Wyss Institute at Harvard University, PhD from UTEP Department of Chemistry & Biochemistry, and XiuJun Li full Professor in the Department of Chemistry and Biochemistry and of Forensic Science, & Environmental Science and Engineering, at the University of Texas at El Paso (UTEP) have developed a new portable device for cancer detection that offers several advantages over traditional methods: Key Features: - Low cost (a few dollars per device, <8 cents per assay) - Provides results in about 1 hour (vs. 12-16 hours for traditional methods) - Approximately 10 times more sensitive than traditional methods - Portable and doesn't require specialized instruments - Can detect both CEA colorectal and PSA prostate cancer biomarkers - Uses a "paper-in-polymer-pond" structure to analyze blood samples How it works: - U...
Read more

Cancer patients and doctors team up to change how cancer drugs are tested | Fox News

Cancer patients and doctors team up to change how cancer drugs are tested | Fox News foxnews.com Associated Press For cancer patients, the harsh side effects of powerful drugs have long been the trade-off for living longer. Now, patients and doctors are questioning whether all that suffering is necessary. They’ve ignited a movement to radically change how new cancer drugs are tested, with the U.S. Food and Drug Administration urging drugmakers to do a better job at finding the lowest effective dose, even if it takes more time. Advances in treatment mean millions of people are surviving for years with incurable cancers. Jill Feldman, 54, of Deerfield, Illinois, has lived 15 years with lung cancer , thanks to that progress. Her parents both died of lung cancer months after their diagnoses. But her cancer drug causes joint pain, fatigue and mouth sores that m...
Read more